CA3202389A1 - Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use - Google Patents
Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of useInfo
- Publication number
- CA3202389A1 CA3202389A1 CA3202389A CA3202389A CA3202389A1 CA 3202389 A1 CA3202389 A1 CA 3202389A1 CA 3202389 A CA3202389 A CA 3202389A CA 3202389 A CA3202389 A CA 3202389A CA 3202389 A1 CA3202389 A1 CA 3202389A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- spacer
- polypeptide
- positions
- isolated polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126736P | 2020-12-17 | 2020-12-17 | |
| US63/126,736 | 2020-12-17 | ||
| PCT/US2021/063920 WO2022133148A1 (en) | 2020-12-17 | 2021-12-16 | Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202389A1 true CA3202389A1 (en) | 2022-06-23 |
Family
ID=80123475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202389A Pending CA3202389A1 (en) | 2020-12-17 | 2021-12-16 | Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2024218747A1 (en) * | 2023-02-10 | 2025-08-28 | Hangzhou Sciwind Biosciences Co., Ltd. | Polypeptide and derivative thereof, composition, and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100256056A1 (en) | 2007-09-07 | 2010-10-07 | Zheng Xin Dong | Analogues of exendin-4 and exendin-3 |
| EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
| JP6165168B2 (ja) * | 2011-12-22 | 2017-07-19 | ファイザー・インク | 抗糖尿病化合物 |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR20240037175A (ko) * | 2016-05-16 | 2024-03-21 | 인타르시아 세라퓨틱스 인코포레이티드 | 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법 |
| CA3025592A1 (en) * | 2016-06-09 | 2017-12-14 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
-
2021
- 2021-12-16 CN CN202180089098.0A patent/CN116917311A/zh active Pending
- 2021-12-16 US US17/553,381 patent/US12084485B2/en active Active
- 2021-12-16 KR KR1020237023789A patent/KR20230156689A/ko active Pending
- 2021-12-16 MX MX2023007224A patent/MX2023007224A/es unknown
- 2021-12-16 CA CA3202389A patent/CA3202389A1/en active Pending
- 2021-12-16 EP EP21851897.5A patent/EP4263587A1/en not_active Withdrawn
- 2021-12-16 IL IL303686A patent/IL303686A/en unknown
- 2021-12-16 AU AU2021400738A patent/AU2021400738A1/en active Pending
- 2021-12-16 JP JP2023537184A patent/JP2024502740A/ja active Pending
- 2021-12-16 WO PCT/US2021/063920 patent/WO2022133148A1/en not_active Ceased
- 2021-12-16 AR ARP210103539A patent/AR124395A1/es unknown
- 2021-12-17 TW TW110147341A patent/TW202237628A/zh unknown
-
2023
- 2023-06-15 ZA ZA2023/06290A patent/ZA202306290B/en unknown
-
2024
- 2024-07-22 US US18/779,857 patent/US20250034225A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024502740A (ja) | 2024-01-23 |
| EP4263587A1 (en) | 2023-10-25 |
| US12084485B2 (en) | 2024-09-10 |
| WO2022133148A1 (en) | 2022-06-23 |
| CN116917311A (zh) | 2023-10-20 |
| TW202237628A (zh) | 2022-10-01 |
| ZA202306290B (en) | 2026-03-25 |
| AR124395A1 (es) | 2023-03-22 |
| AU2021400738A1 (en) | 2023-07-13 |
| IL303686A (en) | 2023-08-01 |
| US20230063420A1 (en) | 2023-03-02 |
| KR20230156689A (ko) | 2023-11-14 |
| MX2023007224A (es) | 2023-09-05 |
| US20250034225A1 (en) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI700291B (zh) | 升糖素及glp-1共激動劑化合物 | |
| JP6534927B2 (ja) | グルカゴン類似体 | |
| CN106715466B (zh) | 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽-4衍生物 | |
| KR101667948B1 (ko) | 글루카곤 유사체 | |
| CN104395338B (zh) | 人胰岛淀粉样多肽类似物 | |
| US7091183B1 (en) | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) | |
| US9260534B2 (en) | Site-directed PEG-modified exendin-4 analogs and uses thereof | |
| CN112409460A (zh) | 一类glp-1/胰高血糖素受体双重激动剂及其应用 | |
| TW201808989A (zh) | 升糖素受體選擇性多肽和彼之使用方法 | |
| CN101822820A (zh) | 稳定蛋白质制剂 | |
| US20090202494A1 (en) | Combined use of glp-1 agonists and gastrin for regulating blood glucose levels | |
| JP7580403B2 (ja) | Ｇｌｐ１／２二重アゴニストの非経口医薬組成物 | |
| EP2565202A1 (en) | Peptide for improving in vivo stability of physiologically active substance or the like and physiologically active substance with improved in vivo stability | |
| RS67940B1 (sr) | Materijali i postupci za lečenje friedreich-ove ataksije | |
| ZA200602000B (en) | Albumin-binding derivatives of therapeutic peptides | |
| KR20160012992A (ko) | 소도 신생 펩티드 및 이의 유사체를 사용하는 조성물 및 방법 | |
| WO2011153491A2 (en) | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets | |
| US20220119473A1 (en) | Acylated oxyntomodulin peptide analog | |
| KR20210091705A (ko) | 인간 아밀린 유사체 폴리펩타이드 및 사용 방법 | |
| AU2024203093A1 (en) | Polypeptide compounds and use thereof in the prevention or treatment of diabetes or diagnostic compounds | |
| US10010577B2 (en) | Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide | |
| CN114621327B (zh) | GLP-1、GIP和Gcg多重受体激动蛋白质 | |
| KR20230156689A (ko) | 지속형 글루카곤 유사 폴리펩티드-1(glp-1) 수용체작용제 및 사용 방법 | |
| KR20230039604A (ko) | 지속형 글루카곤 수용체 선택적 펩타이드 및 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251212 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251212 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260209 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260209 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260210 |